Reduction of circulating plasminogen using a specific Plg ASO significantly reduced subcutaneous tumor volume over time (Fig. 7A) and the final tumor mass (Fig. 7A) of human Pa02C tumors relative to control ASO treated mice. The gene discussed is PLG; the disease is neoplasm.